• Epidemiology and Risk Factors
• 23 min
  1. Coronary heart disease epidemiology: global context for a new genetic understanding

  • Prof. Harry Hemingway
• 44 min
  2. Cardiovascular risk factors

  • Dr. Michal Vrablik
• 65 min
  3. Lipoproteins

  • Prof. Arnold von Eckardstein
• 39 min
  4. Thrombotic risk factors for cardiovascular disease

  • Prof. Gordon Lowe
• 20 min
  5. Lipoprotein(a)

  • Dr. Jaimini Cegla
• Biology of Coronary Heart Disease
• 42 min
  6. Plaque rupture

  • Prof. Petri Kovanen
• 56 min
  7. Transcription factors and complex disease development

  • Dr. Ines Pineda-Torra
• 39 min
  8. Animal models to explore cardiovascular disease

  • Prof. Martin Merkel
• Treatment
• 26 min
  9. Diagnosis and treatment of dyslipidemias

  • Prof. Anton Stalenhoef
• 31 min
  10. Key drug discovery challenges in cardiovascular medicine

  • Dr. Dan Swerdlow
  • Dr. Michael V. Holmes
• Genetics
• 50 min
  11. Moving from GWAS hits to functional variants

  • Prof. Steve Humphries
• 51 min
  12. Heart disease genes and SNPs

  • Prof. Steve Humphries
• 39 min
  13. Familial hypercholesterolaemia: genetic causes and treatment

  • Prof. Steve Humphries
• 22 min
  14. Familial hypercholesterolaemia: cascade testing and monogenic vs. polygenic causes

  • Prof. Steve Humphries
• 28 min
  15. Familial hypercholesterolaemia: case studies, universal screening and novel mutations

  • Prof. Steve Humphries
• 52 min
  16. Genetics of cardiovascular disease

  • Prof. Philippa Talmud
• 54 min
  17. The genetics of CHD: moving research findings into patient benefit

  • Prof. Steve Humphries
• 35 min
  18. Mendelian randomisation: using genetics to determine causality

  • Dr. Tina Shah
• 33 min
  19. The genetics of abdominal aortic aneurysm

  • Dr. Seamus Harrison
• 49 min
  20. Genome scans for hypertension

  • Prof. Patricia Munroe
• 43 min
  21. Telomeres and cardiovascular disease

  • Dr. Jess Buxton
• 33 min
  22. Translational applications of cardiovascular genomics: opportunities and challenges

  • Dr. Aroon Hingorani
• 26 min
  23. Genetics of hypertrophic cardiomyopathy (HCM)

  • Dr. Petros Syrris
• Archived Lectures *These may not cover the latest advances in the field
• 44 min
  24. Gene-environment interaction and oxidative stress in cardiovascular disease

  • Dr. Jeffrey Stephens
• 34 min
  25. Gene therapy as a therapeutic option for lipoprotein lipase deficiency

  • Dr. Jan Albert Kuivenhoven
• 60 min
  26. Cardiovascular diseases: from epidemiology to nutritional interventions

  • Dr. Antonis Zampelas
• 45 min
  27. Genetic testing for CHD risk: fact or fiction?

  • Prof. Steve Humphries
• 35 min
  28. Pharmacogenetics: progress, pitfalls and clinical potential

  • Prof. Steve Humphries
• 50 min
  29. Familial hyperchlolesterolaemia: a monogenic cause of early CHD

  • Prof. Steve Humphries
• 29 min
  30. Lipid metabolism

  • Dr. Ulrike Beisiegel

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Cardiovascular risk and risk factors
3. Different risk categories
4. CVD - leading cause of adult mortality worldwide
5. Leading causes of death, Canada, 1998
6. CVD mortality, USA, 1980-2003
7. Standardized mortality- Czech Rep., 1990-2006
8. Global burden of cardiovascular disease
9. The EUROASPIRE III study
10. Atherogenesis
11. Atherosclerosis
12. Clinical manifestations of atherosclerosis
13. Risk factors
14. Risk factors for cardiovascular disease
15. Modifiable vs. non-modifiable risk factors
16. The risk is multiplicative
17. Combination of risk factors increases risk of MI
18. Non-modifiable risk factors
19. Modifiable risk factors
20. Dyslipidemia as a significant risk factor for CVD
21. Structure of lipoproteins
22. Classification of dyslipidaemias
23. Types of lipoprotein particles
24. Relationship between cholesterol and CHD risk
25. Relationship of serum cholesterol to mortality
26. LDL cholesterol
27. Relationship between LDL-C and CV event rate
28. Prevalence of raised LDL cholesterol
29. HDL cholesterol
30. Triglycerides
31. Triglyceride levels and LDL phenotypes
32. Impact of TG levels on relative risk (RR) of CHD
33. Apolipoproteins
34. The INTERHEART study
35. Risk of AMI associated with risk factors
36. Risk factors and risk of MI
37. ApoB/ApoA-I as a predictor of risk
38. INTERHEART study conclusion
39. Indicators of plasma atherogenic phenotype
40. CAD risk and HDL particle size
41. HDL protective and risk particles
42. CAD risk and LDL particle size
43. Subfrakce LDL
44. CAD risk and VLDL particle size
45. TG and HDL-C levels determine LP particle size
46. Smoking as a risk factor for CVD
47. Smoking and mortality
48. Cumulative tobacco related death rate worldwide
49. Smoking and MI risk
50. CHD risk and smoking: dose dependence
51. Passive smoking risk
52. Smoking and atherogenesis
53. Adverse effect of smoking on different risk factors
54. Endothelium damage after smoke exposure
55. Prevalence of smoking
56. Diabetes as a risk factor for CVD
57. Diabetes mellitus
58. Estimates of incident of type II diabetes
59. Types of diabetes mellitus
60. The chronic complications of diabetes mellitus
61. Typical lipid profile in patients with/without DM
62. Diabetics at similar risk to non diabetics with CVD
63. Less favourable angioplasty outcome in diabetes
64. Diabetic resistance to CVD preventive strategies
65. Prevalence of diabetes
66. The metabolic syndrome
67. The MetS and associated CVD risk factors
68. Criteria for diagnosis of the metabolic syndrome
69. Prevalence of MetS in the USA
70. MetS and CVD
71. Higher rates of atherosclerosis in MetS patients
72. Overweight and obesity as a risk factor
73. Prevalence of obesity
74. Survival of the fittest
75. How to assess the risk?
76. Risk assessment
77. Why do we assess risk?
78. The SCORE chart
79. Framingham point score
80. Atherosclerosis imaging (1)
81. Atherosclerosis imaging (2)
82. Intima media thickness (IMT)
83. IMT and CV events
84. Carotid IMT measurement
85. IMT of carotid arteries
86. Normal finding on carotid US
87. Pathological finding
88. Carotid IMT is a measure of atherosclerosis
89. Example of atherosclerosis regression, IVUS
90. CT angiography
91. Conclusions

Topics Covered

• Cardiovascular disease burden
• Atherosclerosis as a cause of CVD
• Non-modifiable and modifiable risk factors for CVD
• Dyslipidemia and CVD risk
• Apoproteins as CVD risk predictors
• Quality of lipoprotein particles as an important indicator of lipids associated risk
• Smoking as a CVD risk factor
• Diabetes as a risk factor for CVD
• Metabolic syndrome and CVD risk
• Risk assessment tools
• Atherosclerosis imaging techniques and risk assessment

Links

Series:

• Genetics of Cardiovascular Disease

Categories:

• Clinical Practice

Therapeutic Areas:

• Cardiovascular & Metabolic

Talk Citation

Publication History

• Published on November 24, 2008

Financial Disclosures

• Dr. Michal Vrablik has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.